| Full text | |
| Author(s): Show less - |
Nani, V, Joao
;
Dal Mas, Caroline
[1]
;
Yonamine, Camila M.
[1]
;
Ota, Vanessa K.
[2]
;
Noto, Cristiano
[3, 4]
;
Belangero, I, Sintia
;
Mari, Jair J.
[3]
;
Bressan, Rodrigo
[3]
;
Cordeiro, Quirino
[4]
;
Gadelha, Ary
[3]
;
Hayashi, Mirian A. F.
[1, 5]
Total Authors: 11
|
| Affiliation: | [1] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Pharmacol, Sao Paulo - Brazil
[2] I, Univ Fed Sao Paulo UNIFESP, Dept Genet, Sao Paulo - Brazil
[3] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Psychiat, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo UNIFESP, First Episode Psychosis Program, Sao Paulo - Brazil
[5] Nani, Joao, V, CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto - Brazil
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; v. 23, n. 11, p. 721-730, NOV 2020. |
| Web of Science Citations: | 0 |
| Abstract | |
Background: Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. Methods: ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n = 53) and antipsychotic-naive first-episode psychosis (FEP) patients (n = 45) assessed at baseline (FEB-B) and also after 2 months (FEP2M) of treatment with the atypical antipsychotic risperidone. Results: ACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F = 5.356, df = 2, P =.005) as well as between HC and FEP-2M (post-hoc Tukey's multiple comparisons test, P =.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r = -0.131, P =.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, P =.392), but ACE activity level differences observed between these groups were influenced by age. Conclusions: The importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated. (AU) | |
| FAPESP's process: | 17/25016-8 - Investigation of the treatment response of schizophrenia with risperidone: a pharmacogenetics study in a cohort of first episode of psychosis patients |
| Grantee: | Síntia Iole Nogueira Belangero |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 17/02413-1 - Validation of crotamine as a biomarker and evaluation of its potential use in the therapy of human diseases |
| Grantee: | Mirian Akemi Furuie Hayashi |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 12/08941-6 - The study of oligopeptidases in schizophrenia |
| Grantee: | Camila Miyagui Yonamine Asanuma |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 19/09207-3 - Study of molecular and cellular mechanisms in mental disorders |
| Grantee: | João Victor Silva Nani |
| Support Opportunities: | Scholarships in Brazil - Doctorate |